MentalHealthDaily

Antipsychotic Shortages Caused Drug Switching: 95,968-Patient Claims Study (2026)

by GLOOM

First-generation antipsychotic (FGA) shortages are not just pharmacy annoyances; they force medication changes in people who may have taken years to stabilize on a tolerable regimen. Research Highlights 95,968 patients: Tabah 2026 used Komodo claims data to study people with psychotic-spectrum diagnoses taking shortage-affected first-generation antipsychotics. Switching was not evenly distributed: molindone reached 100% switching, …

Schizophrenia Dementia Risk: Diabetes, Head Injury, Substance Use

by GLOOM

Photoreal illustration of an aging brain with cardiovascular and lifestyle risk imagery, conveying preventable dementia drivers in schizophrenia.

Patients with schizophrenia have substantially elevated dementia risk compared to the general population — roughly 2-3 times the age-adjusted rate — but the specific drivers within the schizophrenia population have been less well characterized. A 2026 case-control study by Ho et al. used population-based data to identify which factors specifically elevate dementia risk among schizophrenia …

Machine Learning Predicts Clozapine Initiation in Schizophrenia

by GLOOM

Photoreal illustration of an electronic health record dashboard with clinical text and a model output highlighted, representing ML prediction in psychiatry.

Clozapine is the only medication with proven efficacy for treatment-resistant schizophrenia, yet most eligible patients wait years before starting it. A 2026 paper by Perfalk and colleagues trains a machine-learning model on routine electronic health record data to flag candidates earlier.1 Research Highlights Clozapine is the only evidence-based treatment for treatment-resistant schizophrenia (TRS), but the …

Lurasidone Improves Positive Symptoms of Schizophrenia More Than Negative

by GLOOM

MHD featured image for Lurasidone PANSS Domains: Positive Symptoms Lead, Negative Lag.

Lurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysis of the JEWEL Phase 3 trial pulls that number apart, looking separately at five symptom domains and at all 30 individual items of the PANSS …

Striatal Dopamine Drops From Psychosis to Schizophrenia Remission

by GLOOM

Photoreal illustration of a brain with the striatum highlighted and dopamine synthesis pathways visualized, representing longitudinal PET imaging in schizophrenia.

The dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story, and most of its supporting evidence has been cross-sectional. A 2026 longitudinal PET study by Schulz and colleagues followed the same 28 patients across psychosis and early remission.1 Research Highlights The dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story. Cross-sectional 18F-DOPA PET …

Risperidone Stroke Risk in Dementia: HR 1.28 Across CVD Subgroups

by GLOOM

Conceptual illustration of cerebral blood vessels and a pill, representing risperidone-associated stroke risk in dementia patients.

The risperidone-stroke link in dementia is one of the longest-running safety signals in geriatric psychiatry, anchoring the FDA’s 2005 black-box warning on atypical antipsychotic mortality. Popular framing reduces it to “antipsychotics cause stroke in dementia” — a true sentence that flattens a multi-axis decision. Choma’s 2025 analysis of UK primary care records is the largest …

Schizophrenia and Aging: Advanced, Not Accelerated

by GLOOM

Two parallel timelines representing chronological vs. biological age in schizophrenia: an early offset at first episode, then parallel trajectories afterward — illustrating advanced rather than accelerated aging.

“Schizophrenia ages you faster” is the headline that gets repeated whenever a new biomarker study lands. The 2026 Fernandez-Egea, Garcia-Rizo and Kirkpatrick review — covering 170 studies across mortality, brain imaging, telomeres, epigenetic clocks, and metabolic markers — pushes back on that framing.2 The aging signal is genuine. “Accelerated” is the part that overshoots for …